An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
Bataller, L.Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain. 2001;124:437–43.CrossRefGoogle ScholarPubMed
3
Armangué, T, Sabater, L, Torres-Vega, E, et al.Clinical and immunological features of opsoclonus-myoclonus syndrome in the era of neuronal cell surface antibodies. JAMA Neurol. 2016;73:417–24.CrossRefGoogle ScholarPubMed
4
Oh, SY, Kim, JS, Dieterich, M.Update on opsoclonus-myoclonus syndrome in adults. J Neurol. 2019;266:1541–8.CrossRefGoogle ScholarPubMed
5
Klaas, JP, Ahlskog, JE, Pittock, SJ, et al.Adult-onset opsoclonus-myoclonus syndrome. Arch Neurol. 2012;69:1598.CrossRefGoogle ScholarPubMed
Erlich, R, Morrison, C, Kim, B, Gilbert, MR, Alrajab, S.ANNA-2: an antibody associated with paraneoplastic opsoclonus in a patient with large-cell carcinoma of the lung with neuroendocrine features--correlation of clinical improvement with tumor response. Cancer Invest. 2004;22:257–61.CrossRefGoogle Scholar
8
Karasaki, T, Tanaka, M.Opsoclonus-myoclonus syndrome associated with non-small cell lung cancer. Asian Cardiovasc Thorac Ann. 2015;23:1113–5.CrossRefGoogle ScholarPubMed